Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation

• Main Authors: Giovanna Lucchini (Author), Erica Dander (Author), Fabio Pavan (Author), Irene Di Ceglie (Author), Adriana Balduzzi (Author), Paolo Perseghin (Author), Giuseppe Gaipa (Author), Alessandra Algarotti (Author), Martino Introna (Author), Alessandro Rambaldi (Author), Attilio Rovelli (Author), Andrea Biondi (Author), Ettore Biagi (Author), Giovanna D'Amico (Author)
• Format: Book
• Published: Hindawi Limited, 2012-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Mesenchymal stromal cells (MSC) are tested in clinical trials to treat graft versus host disease (GvHD) after stem cell transplantation (SCT). In vitro studies demonstrated MSC's broad immunosuppressive activity. As infections represent a major risk after SCT, it is important to understand the...